MyoMarker 3 Plus Profile for Idiopathic Inflammatory Myopathies
Myositis encompasses a heterogeneous group of rare autoimmune inflammatory disorders characterized by profound muscle weakness due to inflammation of skeletal muscle. The three primary subtypes of idiopathic inflammatory myopathies (IIM) are dermatomyositis (characterized by skin involvement and characteristic rashes), polymyositis (primarily muscular involvement), and inclusion body myositis (progressive muscular weakness with specific muscle inclusions).
The pathogenesis of IIM involves environmental triggers combined with genetic predisposition, notably associated with HLA DRB10301 and DQA10501 haplotypes. The disease prevalence ranges between 5 to 22 cases per 100,000 individuals. Autoantibodies, detectable in over 80% of IIM patients, play a crucial role in disease pathophysiology and diagnosis.
Autoantibodies relevant to IIM include:
Myositis-specific antibodies (MSAs):
- Highly specific (>90%) for IIM diagnosis.
- Target proteins such as cytoplasmic aminoacyl-tRNA synthetases and other nuclear or cytoplasmic components.
Myositis-associated antibodies (MAAs):
- Less specific; commonly found in overlap syndromes (e.g., systemic lupus erythematosus, scleroderma).
Antibodies Included in MyoMarker 3 Plus Profile:
Antibody Type Specific Antibodies Tested
- Myositis-specific antibodies (MSA) Anti-Jo-1 (most common), Anti-Mi-2, Anti-MDA5, Anti-TIF-1 gamma, Anti-SAE1, Anti-NXP-2 (P140)
- Myositis-associated antibodies (MAA) Anti-Ro (SS-A), Anti-La (SS-B), Anti-Ku, Anti-U1 RNP
- Other Relevant Antibodies Anti-EJ, Anti-OJ, Anti-PL-7, Anti-PL-12, Anti-PM/Scl-100, Anti-RNA Polymerase III, Anti-SRP, Anti-U2 RNP, Anti-U3 RNP (Fibrillarin)
Both polymyositis and dermatomyositis typically respond to immunosuppressive therapy, commonly corticosteroids (e.g., prednisone/prednisolone at 1-2 mg/kg/day). Additional immunosuppressants and biologics may be considered for refractory disease.
- Diagnosis and classification of idiopathic inflammatory myopathies
- Differentiation of polymyositis and dermatomyositis from other neuromuscular disorders
- Monitoring response to immunosuppressive therapy
Positive Result
Presence of antibodies indicates increased likelihood of idiopathic inflammatory myositis or related overlap syndromes.
Antibody-specific Clinical Associations:
- Anti-Jo-1: Strongly associated with antisynthetase syndrome (myositis, interstitial lung disease, arthritis).
- Anti-Mi-2: Dermatomyositis with good therapeutic response.
- Anti-MDA5: Associated with rapidly progressive interstitial lung disease and amyopathic dermatomyositis.
- Anti-TIF-1 gamma: Strong association with dermatomyositis and malignancy.
- Anti-SRP: Severe necrotizing myopathy with poor corticosteroid response.
- Anti-NXP-2: Juvenile dermatomyositis and calcinosis in children, adult malignancy association.
| Antibodies | Result |
| Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-SRP, Anti-Mi-2, Anti-U3 RNP (Fibrillarin), Anti-U2 RNP, Anti-Ku |
Negative (Not detected) |
| Units | Interpretation |
| <20 units | Negative |
| 20 - 39 units | Weak positive |
| 40 – 80 units | Moderate positive |
| >80 units | Strong positive |
Applies to: Anti-Jo-1, Anti-TIF-1gamma, Anti-MDA-5 (CADM-140), Anti-NXP-2 (P140), Anti-SAE1, Anti-PM/Scl-100, Anti-SS-A, Anti-U1-RNP antibodies.
Serum (SST tube).
Stability
- Ambient: 5-7 days
- Refrigerated: 7-14 days
- Frozen: 60 days
- Ann Rheum Dis. 2007 Oct;66(10):1345-9. [PMID: 17392346]
- Clin Exp Immunol. 2014 Mar;175(3):349-58. [PMID: 23981102]
- Mayo Clin Proc. 2013 Jan;88(1):83-105. [PMID: 23274022]
- Autoimmune Myopathies. [Updated 2023 May 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532860/